Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-24 4:05 pm Purchase | 2025-11-20 | 13G | Phio Pharmaceuticals Corp. PHIO | Orca Capital AG | 700,421 6.500% | 291,160 (+71.14%) | Filing History |
| 2025-11-12 06:10 am Sale | 2025-11-07 | 13G | Phio Pharmaceuticals Corp. PHIO | Orca Capital AG | 409,261 4.900% | -390,739 (-48.84%) | Filing History |
| 2025-11-10 6:36 pm Purchase | 2025-11-03 | 13G | Phio Pharmaceuticals Corp. PHIO | CVI Investments, Inc. | 733,344 9.900% | 642,356 (+705.98%) | Filing History |
| 2025-11-07 5:27 pm Sale | 2025-09-30 | 13G | Phio Pharmaceuticals Corp. PHIO | Mitchell P. Kopin | 430,000 7.000% | -100,171 (-18.89%) | Filing History |
| 2025-11-06 5:00 pm Purchase | 2025-11-03 | 13G | Phio Pharmaceuticals Corp. PHIO | Orca Capital AG | 800,000 9.800% | 519,358 (+185.06%) | Filing History |
| 2025-08-07 4:05 pm Sale | 2025-08-04 | 13G | Phio Pharmaceuticals Corp. PHIO | Orca Capital AG | 280,642 4.900% | -234,323 (-45.50%) | Filing History |
| 2025-02-07 4:09 pm Sale | 2024-12-31 | 13G | Phio Pharmaceuticals Corp. PHIO | CVI Investments, Inc. | 90,988 4.900% | -18,310 (-16.75%) | Filing History |
| 2025-01-23 3:45 pm Purchase | 2024-12-19 | 13G | Phio Pharmaceuticals Corp. PHIO | Orca Capital AG | 514,965 9.900% | 514,965 (New Position) | Filing History |
| 2025-01-17 4:44 pm Purchase | 2025-01-13 | 13G | Phio Pharmaceuticals Corp. PHIO | Mitchell P. Kopin | 530,171 9.990% | 439,184 (+482.69%) | Filing History |
| 2024-12-27 5:05 pm Purchase | 2024-12-19 | 13G | Phio Pharmaceuticals Corp. PHIO | Mitchell P. Kopin | 90,987 4.990% | 45,782 (+101.28%) | Filing History |
| 2024-12-26 2:19 pm Purchase | 2024-12-19 | 13G | Phio Pharmaceuticals Corp. PHIO | CVI Investments, Inc. | 109,298 7.300% | 109,298 (New Position) | Filing History |
| 2024-11-13 11:20 am Purchase | 2024-09-30 | 13G | Phio Pharmaceuticals Corp. PHIO | Mitchell P. Kopin | 45,205 4.990% | 45,205 (New Position) | Filing History |
| 2024-02-06 10:30 am Purchase | 2023-12-31 | 13G | Phio Pharmaceuticals Corp. PHIO | Mitchell P. Kopin | 99,045 9.990% | 99,045 (New Position) | Filing History |
| 2023-02-08 06:07 am Purchase | 2022-12-31 | 13G | Phio Pharmaceuticals Corp. PHIO | Mitchell P. Kopin | 90,204 5.600% | 82,687 (+1100.00%) | Filing History |
| 2022-02-11 07:46 am Purchase | 2021-12-31 | 13G | Phio Pharmaceuticals Corp. PHIO | Mitchell P. Kopin | 7,517 5.700% | 3,393 (+82.28%) | Filing History |
| 2022-01-20 09:51 am Sale | 2021-12-31 | 13G | Phio Pharmaceuticals Corp. PHIO | Empery Asset Management, LP | 7,306 4.990% | -1,024 (-12.30%) | Filing History |
| 2021-02-19 11:21 am Purchase | 2021-02-12 | 13G | Phio Pharmaceuticals Corp. PHIO | Empery Asset Management, LP | 8,330 6.760% | 8,330 (New Position) | Filing History |
| 2021-02-16 10:03 am Sale | 2020-12-31 | 13G | Phio Pharmaceuticals Corp. PHIO | CVI Investments, Inc. | 2,119 4.000% | -1,846 (-46.55%) | Filing History |
| 2021-01-29 06:18 am Purchase | 2020-12-31 | 13G | Phio Pharmaceuticals Corp. PHIO | Mitchell P. Kopin | 4,124 7.200% | 2,380 (+136.51%) | Filing History |
| 2021-01-05 07:45 am Purchase | 2020-12-31 | 13G | Phio Pharmaceuticals Corp. PHIO | SABBY MANAGEMENT LLC | 2,671 11.000% | 951 (+55.33%) | Filing History |